Part 4/8:
The challenges faced by CAR-T therapies extend beyond initial sales. The manufacturing process itself is labyrinthine. CAR-T involves extracting a patient's T cells, genetically modifying them in a lab, and reinfusing them into the patient’s body. This requires meticulous logistical coordination that can vary dramatically from patient to patient, heavily influenced by their individual health situations. Such variability can lead to unpredictable results and increases the complexity of treatment.